Perceived and Actual Risks of College Students for Developing
... Diabetes affected 26 million (8.3%) people in the United States in 2010 (Centers for Disease Control and Prevention [1]. Of those, 10.9 million were older than 65 years, approximately 1.9 million new cases were over the age of 20 years, but 215,000 individuals were younger than 20 years old. Researc ...
... Diabetes affected 26 million (8.3%) people in the United States in 2010 (Centers for Disease Control and Prevention [1]. Of those, 10.9 million were older than 65 years, approximately 1.9 million new cases were over the age of 20 years, but 215,000 individuals were younger than 20 years old. Researc ...
Document
... failure (866 [14·1%] of 6137 patients). Type 2 diabetes was positively associated with peripheral arterial disease (adjusted HR 2·98 [95% CI 2·76–3·22]), ischaemic stroke (1·72 [1·52–1·95]), stable angina (1·62 [1·49–1·77]), heart failure (1·56 [1·45–1·69]), and non-fatal myocardial infarction (1·54 ...
... failure (866 [14·1%] of 6137 patients). Type 2 diabetes was positively associated with peripheral arterial disease (adjusted HR 2·98 [95% CI 2·76–3·22]), ischaemic stroke (1·72 [1·52–1·95]), stable angina (1·62 [1·49–1·77]), heart failure (1·56 [1·45–1·69]), and non-fatal myocardial infarction (1·54 ...
View supplementary material
... - patients who did not attend more than 4 out of the planned 6 visits following randomisation. We do not except any missing values for the time to a clinical outcomes as all deaths and admissions to Danish hospitals are registered in the Civil Registry and the National Patient Registry and were adju ...
... - patients who did not attend more than 4 out of the planned 6 visits following randomisation. We do not except any missing values for the time to a clinical outcomes as all deaths and admissions to Danish hospitals are registered in the Civil Registry and the National Patient Registry and were adju ...
The Prevalence and Risk Factors of Osteoporosis among a Saudi
... has been mentioned before. The use of oral hypoglycemic agents was another predictor for the development of osteopenia or osteoporosis as indicated by the current study. Based on our findings, patients on oral hypoglycemic medications have a nearly three times risk of developing osteopenia and more ...
... has been mentioned before. The use of oral hypoglycemic agents was another predictor for the development of osteopenia or osteoporosis as indicated by the current study. Based on our findings, patients on oral hypoglycemic medications have a nearly three times risk of developing osteopenia and more ...
Type 2 Diabetes Mellitus: The Grand Overview
... It is now clear that high-risk individuals can be identified, and intervention trials are underway to test the hypothesis that Type 2 diabetes (and its attendant cardiovascular risks) can be prevented. The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP NIDDM) in Canada and Europe has ...
... It is now clear that high-risk individuals can be identified, and intervention trials are underway to test the hypothesis that Type 2 diabetes (and its attendant cardiovascular risks) can be prevented. The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP NIDDM) in Canada and Europe has ...
Exercise training: can it improve cardiovascular health in patients
... that precede the development of diabetes also have adverse effects on cardiovascular health and may also be prevented or delayed by regular exercise. Pre-diabetes is a metabolic condition that is between normal glucose homoeostasis and diabetes,6 and its prevalence in 2000 was estimated at nearly 12 ...
... that precede the development of diabetes also have adverse effects on cardiovascular health and may also be prevented or delayed by regular exercise. Pre-diabetes is a metabolic condition that is between normal glucose homoeostasis and diabetes,6 and its prevalence in 2000 was estimated at nearly 12 ...
Exercise training: can it improve cardiovascular health in patients
... that precede the development of diabetes also have adverse effects on cardiovascular health and may also be prevented or delayed by regular exercise. Pre-diabetes is a metabolic condition that is between normal glucose homoeostasis and diabetes,6 and its prevalence in 2000 was estimated at nearly 12 ...
... that precede the development of diabetes also have adverse effects on cardiovascular health and may also be prevented or delayed by regular exercise. Pre-diabetes is a metabolic condition that is between normal glucose homoeostasis and diabetes,6 and its prevalence in 2000 was estimated at nearly 12 ...
RECIPES FOR SUCCESS
... done on another day unless there is unequivocal hyperglycemia and acute metabolic decompensation www.diabetesclinic.ca ...
... done on another day unless there is unequivocal hyperglycemia and acute metabolic decompensation www.diabetesclinic.ca ...
Hospital based epidemiological study for diabetic retinopathy: study
... has been approved by the Liaoning Provincial Health Department (Liaoning Medical Peak Construction Projects Foundation)and the study confronts important ethical considerations. The study has been divided into 6 steps. ...
... has been approved by the Liaoning Provincial Health Department (Liaoning Medical Peak Construction Projects Foundation)and the study confronts important ethical considerations. The study has been divided into 6 steps. ...
Acute Complications and Drug Misuse Are Important Causes of
... CONCLUSIONS — The Yorkshire Register data have enabled an investigation of mortality rates on 4,200 subjects diagnosed continuously from 0 –29 years of age, comprising one of the largest and most recent population-based series in this age range. The Yorkshire Register is 98% complete in terms of asc ...
... CONCLUSIONS — The Yorkshire Register data have enabled an investigation of mortality rates on 4,200 subjects diagnosed continuously from 0 –29 years of age, comprising one of the largest and most recent population-based series in this age range. The Yorkshire Register is 98% complete in terms of asc ...
Perioperative diabetic and hyperglycemic management issues
... large part because of concerns over the systemic effects of unrecognized hypoglycemia, particularly the neuroglycopenic sequelae. Severe hypoglycemia may result in somnolence, unconsciousness, seizures, and, if sustained for a sufficient period, irreversible neurologic insult or death (30). Recognit ...
... large part because of concerns over the systemic effects of unrecognized hypoglycemia, particularly the neuroglycopenic sequelae. Severe hypoglycemia may result in somnolence, unconsciousness, seizures, and, if sustained for a sufficient period, irreversible neurologic insult or death (30). Recognit ...
LONG TERM COMPLICATIONS OF DIABETES – A REVIEW
... Dyslipidemia is a major risk factor for coronary heart disease, which is the most common cause of mortality in patients with DM. In addition to glycemic, weight and blood pressure control, lipid control is also a part of the intensive multifactorial clinical management for DM. Usually, the lipids ar ...
... Dyslipidemia is a major risk factor for coronary heart disease, which is the most common cause of mortality in patients with DM. In addition to glycemic, weight and blood pressure control, lipid control is also a part of the intensive multifactorial clinical management for DM. Usually, the lipids ar ...
Diabetes Epidemic Is a Worldwide Threat
... begins with education, both of our patients and of the public at large. The increasing recognition of diabetes as a serious disease and one of accelerating prevalence can only be helpful. We again have an advantage here in the United States with not only an informed physician community, but also a c ...
... begins with education, both of our patients and of the public at large. The increasing recognition of diabetes as a serious disease and one of accelerating prevalence can only be helpful. We again have an advantage here in the United States with not only an informed physician community, but also a c ...
Thyroid disease in Pregnancy
... • 60% to 70% of people with diabetes have mild to severe nervous system damage • Almost 30% of people with diabetes aged 40 years and older have impaired sensation in the feet • People with diabetes are twice as likely to have depression National Diabetes Fact Sheet, CDC, 2011. http://www.cdc.gov/di ...
... • 60% to 70% of people with diabetes have mild to severe nervous system damage • Almost 30% of people with diabetes aged 40 years and older have impaired sensation in the feet • People with diabetes are twice as likely to have depression National Diabetes Fact Sheet, CDC, 2011. http://www.cdc.gov/di ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... Considerably less is known about the prevalence of the combination of diabetes and heart failure and less information is available on the incidence of the combination of diabetes and heart failure. However the available information indicated that diabetes mellitus is a well known and important risk ...
... Considerably less is known about the prevalence of the combination of diabetes and heart failure and less information is available on the incidence of the combination of diabetes and heart failure. However the available information indicated that diabetes mellitus is a well known and important risk ...
The Glycemic Pentad: Role Of Insulin Analogues
... of cardiovascular events by 1.33 (1.06 -1.67) with respect to an FPG of 75 mg% (12). An effective anti- diabetes regime, therefore, should target FPG, while reducing the variability of FPG as well. While choosing of an oral drug or insulin, one should take these factors into account. Post Prandial P ...
... of cardiovascular events by 1.33 (1.06 -1.67) with respect to an FPG of 75 mg% (12). An effective anti- diabetes regime, therefore, should target FPG, while reducing the variability of FPG as well. While choosing of an oral drug or insulin, one should take these factors into account. Post Prandial P ...
Latent Autoimmune Diabetes in Adults Differs
... The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ...
... The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ...
Guidelines - Diabetes Management
... Initial drug therapy for hypertension may be with ACE inhibitors, ARBs, beta-blockers, calcium channel blockers or diuretics. Additional drugs may be chosen from these classes or another drug class. (A) Minimum of two drug therapy is generally recommended for all diabetics to reduce risk of CAD, CVA ...
... Initial drug therapy for hypertension may be with ACE inhibitors, ARBs, beta-blockers, calcium channel blockers or diuretics. Additional drugs may be chosen from these classes or another drug class. (A) Minimum of two drug therapy is generally recommended for all diabetics to reduce risk of CAD, CVA ...
Diabetes and hearing loss
... investigators evaluated hearing impairment using high-frequency (3000-, 4000-, 6000-, and 8000Hz) as well as low- or middle-frequency (500-, 1000-, and 2000-Hz) at two levels of severity (>25 and >40 dB HL) in both the worse and better ear Bainbridge, K., Hoffman, H., & Cowie, C. (2008). Diabetes an ...
... investigators evaluated hearing impairment using high-frequency (3000-, 4000-, 6000-, and 8000Hz) as well as low- or middle-frequency (500-, 1000-, and 2000-Hz) at two levels of severity (>25 and >40 dB HL) in both the worse and better ear Bainbridge, K., Hoffman, H., & Cowie, C. (2008). Diabetes an ...
Small-Cap Research
... AB101 as a weekly subcutaneous basal insulin therapy in patients with diabetes mellitus. We view these results as encouraging, with no initial undesirable effects of insulin bursts or hypoglycemia seen in the animal models. We believe the preclinical data supports moving forward with clinical progra ...
... AB101 as a weekly subcutaneous basal insulin therapy in patients with diabetes mellitus. We view these results as encouraging, with no initial undesirable effects of insulin bursts or hypoglycemia seen in the animal models. We believe the preclinical data supports moving forward with clinical progra ...
Review Article Glycated Haemoglobin — a marker and predictor of
... haemoglobin is associated with increased cardiovascular mortality in non-diabetic chronic kidney disease.19 Every 1% increase in HbA1c is associated with a 20 to 30% increase in cardiovascular events, and all cause mortality in men and women independent of diabetic status.20 Elevated HbA1c levels ha ...
... haemoglobin is associated with increased cardiovascular mortality in non-diabetic chronic kidney disease.19 Every 1% increase in HbA1c is associated with a 20 to 30% increase in cardiovascular events, and all cause mortality in men and women independent of diabetic status.20 Elevated HbA1c levels ha ...
Perspectives from NIDDK
... “Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.” ...
... “Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.” ...
insulin deficiency
... improve sensitivity to insulin in several tissues by binding to PPAR-γ receptors, leading to increased expression of glucose transporters. The agent causes weight gain when used as monotherapy and in combination with insulin. Serum triglyceride values fall, whereas both LDL and HDL cholesterol value ...
... improve sensitivity to insulin in several tissues by binding to PPAR-γ receptors, leading to increased expression of glucose transporters. The agent causes weight gain when used as monotherapy and in combination with insulin. Serum triglyceride values fall, whereas both LDL and HDL cholesterol value ...
Why do we have - Home - KSU Faculty Member websites
... • Strong family history of diabetes add to other factors like obesity. • Ethnicity and family history show the genetic factor in type 2 diabetes. ...
... • Strong family history of diabetes add to other factors like obesity. • Ethnicity and family history show the genetic factor in type 2 diabetes. ...
Featured Cases: Therapeutic Advances in Type 2 Diabetes Treatment
... and without causing any excessive weight gain. ...
... and without causing any excessive weight gain. ...
Rosiglitazone
Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits.Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the U.S. From November 2011 until November 2013, the federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies. In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label randomized control trial), which failed to show heart infarct risks associated with the drug.In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks. It was withdrawn from the market in the UK and India in 2010, and in New Zealand and South Africa in 2011.